Pharmaceutical companies such as Xianju Pharmaceutical and Minova accept surveys from more than 10 institutions

 In a blink of an eye, November has come to an end.
Looking back on this month, the pharmaceutical industry is still an area of ​​great concern to institutions
.
For example, Xianju Pharmaceutical, Manova, Yunnan Baiyao, etc.
all indicated that they have accepted research from many institutions
.
Xianju Pharmaceutical accepts investigations from 15 securities brokerage institutions.
On November 26, 2021, Xianju Pharmaceutical issued an announcement stating that 15 institutions will investigate the company on November 25, 2021
.
These 15 institutions are Industrial Securities, Dongxing Securities, Guangyin Wealth Management, Shennong Investment, Zheshang Fund, Tongtai Fund, Zeyuan Asset Management, Junhe Capital, Ping An Asset Management, Rongtong Fund, Robeco Investment, and Shanshu Assets , Shanghai Investment Morgan, SDIC UBS, Zhijiage Investment Management
.
Xianju Pharmaceutical is a pharmaceutical company integrating raw materials and preparations.
The company has 22 products for consistency evaluation, 9 of which have been declared; 18 new imitation products, of which 6 have been declared
.
In the survey, Xianju Pharmaceutical said that this year's respiratory products still maintained a high growth, which mainly came from the growth of two varieties of mometasone furoate nasal spray and tiotropium bromide powder spray
.
In addition, in answering the company’s mid- and long-term strategic positioning and future development layout, Xianju Pharmaceutical said that the company has an integrated industrial chain of APIs and preparations, a complete manufacturing system (Chinese factories and Italian factories), and sales both domestic and foreign.
The market has its own characteristics in segmented areas
.
The company will focus on the field of steroid hormones for a long time, complete and refine the industry chain, continuously enrich the structure of APIs and preparations, focus on the improvement of comprehensive capabilities, continue to enhance the value of products, and form small and beautiful industry characteristics in the industry
.
Create a global steroid hormone industry chain supplier with complete products, deep research, high quality, and excellent overall cost
.
According to data from the third quarter report of Xianju Pharmaceutical, the company's operating income in the third quarter of 2021 increased by 13.
07% year-on-year to 3.
317 billion yuan; non-net profit increased by 30.
29% year-on-year to 448 million yuan
.
The agency believes that in the first three quarters of 2021, the company's performance will maintain a strong growth of 30%
.
Minova Pharmaceuticals Receives Investigation from 12 Institutions.
On November 26, 2021, Minova Pharmaceuticals released a record of investor relations activities.
The company accepted investigations from 12 institutions on November 24, 2021.
The types of institutions were Others, Fund Companies, Securities companies, Sunshine private equity institutions
.
Menova Pharmaceuticals is currently mainly engaged in the research and development, production and sales of specialty APIs (including intermediates) and finished drugs.
Its main categories include cardiovascular and gastrointestinal drugs
.
The company's main products are valsartan, losartan, perindopril, rosuvastatin, atorvastatin, clopidogrel and esomeprazole, ticlopidine, duloxetine and mirtazapin
.
In the survey, Sino-American Novartis stated that the company plans to submit 10-15 products for registration in China and Europe for approval each year
.
In terms of production capacity, Minova has made full preparations.
The company’s wholly-owned subsidiary, Ningbo Minova Tiankang Pharmaceutical Co.
, Ltd.
’s "3 billion tablets (tablets) export solid preparation construction project" is expected to be in June-July 2022.
It can be put into production, and this is a dual-certified production line in China and Europe
.
In terms of category, Manova has already deployed a broad range of generic drugs whose patents are about to expire or have expired, from raw materials to preparations
.
Menova Pharmaceuticals also stated that, as a company that has more than ten years of experience in cooperation with major European customers, it has a complete R&D, production, technology, and EHS management system.
It also has the European Medicines Quality Administration and the U.
S.
Food and Drug Administration certification.
Compliance companies are the beneficiaries of the "Notice on the Implementation Plan for Promoting the High-quality Development of the API Industry"
.
Yunnan Baiyao receives investigations from 2 institutions.
On November 18, 2021, Yunnan Baiyao released a record of investor relations activities.
The company accepted investigations from 2 institutions on November 17, 2021.
The type of institution was other and overseas institutions
.
Yunnan Baiyao is a company that mainly deals in chemical raw materials, chemical preparations, Chinese patent medicines, Chinese medicinal materials, and biological products
.
The company's products are mainly Yunnan Baiyao series, Panax notoginseng series and Yunnan ethnic characteristic medicine series, with a total of more than 200 products in 17 dosage forms
.
When questioned by investors, "Will the centralized procurement of Chinese patent medicines affect the company's varieties of Chinese medicines?", Yunnan Baiyao stated that the company's central products (aerosols, baiyao ointments, baiyao capsules, powders, band-aids) are not expected to be affected by business operations.
The impact of centralized procurement
.
In terms of specialty medicines, objectively, the use of different medicinal materials, different brands and manufacturers may have certain differences in ensuring the supply of raw materials and the quality of medicines.
If the future policy orientation is to reduce prices as the main demand, I believe the country will also introduce Corresponding measures shall be taken to prevent the occurrence of low-priced Chinese patent medicines of average quality being selected, while high-quality Chinese patent medicines are sold out at high prices
.
Therefore, products with high quality, high clinical value, and relatively fair prices like Yunnan Baiyao also have good competitiveness compared with other competing products.
In the future, with the company's digital transformation represented by the digital 37 industry platform A comprehensive upgrade will certainly build a stronger wall to control the source of the raw material quality of the company's drugs, and further enhance the company's proprietary Chinese medicine products
.
In addition, Yunnan Baiyao stated that the main sales area of ​​the company's specialty drugs is mainly in the OTC channel of chain pharmacies.
If the national centralized procurement policy extends to pharmacies in the future, it will be a challenge that every pharmaceutical company will face.
Product strength and lean management will be drugs.
In the direction of corporate competition, the company’s specialty medicines have always adhered to the route of low price and high quality.
The company will continue to make good products and produce reassuring medicines that people can trust
.